[Andexanet alfa (ONDEXXYA® for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence].

Abstract

Andexanet alfa is a modified recombinant human factor Xa (FXa) that was designed to serve as a binding target for FXa inhibitors as decoy protein. It sequesters FXa inhibitors from binding to endogenous FXa, thereby reversing anticoagulant effect of FXa inhibitors. Andexanet alfa has been approved in March 2022 in Japan for patients with life-threatening or uncontrolled bleeding while on treatment with a FXa inhibitor, apixaban, rivaroxaban, or edoxaban tosilate hydrate. It is administered via two dosing regimens, based on the type of FXa inhibitor, dose, and time since the last dose. In nonclinical studies, andexanet alfa significantly inhibited bleeding induced by FXa inhibitors in animal bleeding models. In the development for Japanese patients, the following two clinical studies have been conducted to confirm the efficacy and safety. First, safety and the reversal effect of andexanet alfa on the FXa inhibitor-mediated anticoagulant activity in healthy adults were confirmed in the overseas phase 2 study including Japanese subjects. Next, the reversal effect of andexanet alfa on the anticoagulation activity and the hemostasis were demonstrated in patients with acute major bleeding while on FXa inhibitor treatment in the global phase 3b/4 study (ANNEXA-4 study). The subgroup analysis of Japanese population showed that the efficacy and safety results were consistent with those of overall population. Andexanet alfa is the first approved reversal agent for FXa inhibitors in Japan and is expected to contribute to the improvement of prognosis in patients with fatal and/or uncontrolled bleeding by timely reversing anticoagulant effect of FXa inhibitors.

• Authors: Toshitaka Yajima, Mitsuo Higashimori, Chie Takata, Toshikazu Sasabe
• Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica (Nihon Yakurigaku Zasshi) Vol. 158 Issue 1 Pg. 89-100 ( 2023) ISSN: 0015-5691 [Print] Japan
• PMID: 36596498 (Publication Type: English Abstract, Journal Article)

Chemical References

• Factor Xa
• Factor Xa Inhibitors
• PRT064445
• Recombinant Proteins

Topics

• Adult
• Animals
• Humans
• Factor Xa (administration & dosage)
• Factor Xa Inhibitors (adverse effects)
• Hemorrhage (chemically induced, prevention & control)
• Injections, Intravenous
• Recombinant Proteins (administration & dosage)
• Clinical Trials, Phase III as Topic
• Clinical Trials, Phase IV as Topic